

# MairÃ©ad Mcnamara

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3483355/publications.pdf>

Version: 2024-02-01

144  
papers

6,127  
citations

136885

32  
h-index

76872

74  
g-index

145  
all docs

145  
docs citations

145  
times ranked

9908  
citing authors

#	ARTICLE	IF	CITATIONS
1	Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy. <i>British Journal of Cancer</i> , 2022, 126, 693-705.	2.9	18
2	Molecular Profiling of Well-Differentiated Neuroendocrine Tumours: The Role of ctDNA in Real-World Practice. <i>Cancers</i> , 2022, 14, 1017.	1.7	2
3	Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1198-1208.	0.5	3
4	Targeted Therapies for Perihilar Cholangiocarcinoma. <i>Cancers</i> , 2022, 14, 1789.	1.7	7
5	Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy. <i>Acta OncolÃ³gica</i> , 2022, 61, 583-590.	0.8	4
6	Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary. <i>British Journal of Cancer</i> , 2022, 127, 531-540.	2.9	11
7	Distal migration of a partially covered duodenal stent requiring emergency surgical extraction. <i>International Journal of Gastrointestinal Intervention</i> , 2022, 11, 89-93.	0.1	0
8	Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence. <i>Annals of Surgical Oncology</i> , 2022, 29, 5568-5577.	0.7	4
9	Use of the Rockwood Clinical Frailty Scale in patients with advanced hepatopancreaticobiliary malignancies. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1009-1015.	1.1	2
10	Systemic therapies in advanced hepatocellular carcinoma: How do older patients fare?. <i>European Journal of Surgical Oncology</i> , 2021, 47, 583-590.	0.5	7
11	Outcomes in older patients with biliary tract cancer. <i>European Journal of Surgical Oncology</i> , 2021, 47, 569-575.	0.5	5
12	A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). <i>Oncologist</i> , 2021, 26, e669-e678.	1.9	15
13	In Reply. <i>Oncologist</i> , 2021, 26, e903-e904.	1.9	0
14	HPB cancers in older patients   inclusion of older/senior patients in clinical trials. <i>European Journal of Surgical Oncology</i> , 2021, 47, 597-602.	0.5	4
15	Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 94, 102168.	3.4	6
16	Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103328.	2.0	25
17	The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 3779.	1.7	16
18	Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant?. <i>Cancers</i> , 2021, 13, 4152.	1.7	4

#	ARTICLE	IF	CITATIONS
19	Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102258.	3.4	45
20	The Potential Role of Liquid Biopsies in Advancing the Understanding of Neuroendocrine Neoplasms. <i>Journal of Clinical Medicine</i> , 2021, 10, 403.	1.0	4
21	Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 101, 102299.	3.4	3
22	Editorial comment on: development and external validation of a model to predict overall survival in patients with resected gallbladder cancer. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 11, 0-0.	0.7	0
23	Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis. <i>Nature Communications</i> , 2021, 12, 7336.	5.8	40
24	Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2020, 112, 200-210.	3.0	90
25	Current standards and future perspectives in adjuvant treatment for biliary tract cancers. <i>Cancer Treatment Reviews</i> , 2020, 84, 101936.	3.4	73
26	Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study. <i>Cancer Medicine</i> , 2020, 9, 6196-6204.	1.3	20
27	Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs). <i>Cancers</i> , 2020, 12, 1988.	1.7	12
28	Fibrolamellar carcinoma: Challenging the challenge. <i>European Journal of Cancer</i> , 2020, 137, 144-147.	1.3	5
29	Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. <i>Cancer Treatment Reviews</i> , 2020, 89, 102084.	3.4	61
30	Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 1682-1688.	0.5	13
31	The assessment of pancreatic exocrine function in patients with inoperable pancreatic cancer: In need of a new gold-standard. <i>Pancreatology</i> , 2020, 20, 668-675.	0.5	12
32	NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). <i>BMI Open</i> , 2020, 10, e034527.	0.8	11
33	Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091529.	1.4	17
34	NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials. <i>Medical Oncology</i> , 2020, 37, 61.	1.2	9
35	Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial. <i>TH Open</i> , 2020, 04, e107-e112.	0.7	16
36	Molecular targeted therapies: Ready for 'prime time' in biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 170-185.	1.8	226

#	ARTICLE	IF	CITATIONS
37	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 1109-1117.	1.8	25
38	Extrapulmonary poorly differentiated NECs, including molecular and immune aspects. <i>Endocrine-Related Cancer</i> , 2020, 27, R219-R238.	1.6	22
39	Clinical and Translational Research Challenges in Biliary Tract Cancers. <i>Current Medicinal Chemistry</i> , 2020, 27, 4756-4777.	1.2	21
40	NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). <i>Future Oncology</i> , 2020, 16, 1069-1081.	1.1	15
41	Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours. <i>World Journal of Clinical Oncology</i> , 2020, 11, 205-216.	0.9	4
42	RELEVANT study: Patient (Pt) and physician (PI) perspectives on meaningful outcomes in advanced pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 150-150.	0.8	0
43	Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. <i>Scientific Reports</i> , 2019, 9, 11610.	1.6	36
44	Response to: Assessing the risk of bias and publication bias should be integral parts of the systematic review. <i>European Journal of Cancer</i> , 2019, 118, 189.	1.3	0
45	<p>Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 7537-7556.	0.9	3
46	Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice. <i>Journal of Clinical Medicine</i> , 2019, 8, 1630.	1.0	10
47	Response to letter to the editor: The impact of the nodal status and resection margin on the effectiveness of adjuvant chemotherapy for pancreatic cancer: It calls for more careful evaluation. <i>Journal of Surgical Oncology</i> , 2019, 120, 1055-1055.	0.8	0
48	Outcomes in patientsâ€™â€™â€™80Â years with a diagnosis of a hepatopancreaticobiliary (HPB) malignancy. <i>Medical Oncology</i> , 2019, 36, 85.	1.2	6
49	&lt;p&gt;Biliary tract cancers: current knowledge, clinical candidates and future challenges&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 2623-2642.	0.9	78
50	Adjuvant chemotherapy and outcomes in patients with nodal and resection marginâ€™negative pancreatic ductal adenocarcinoma: A systematic review and metaâ€™analysis. <i>Journal of Surgical Oncology</i> , 2019, 119, 932-940.	0.8	11
51	A strategy for early detection of response to chemotherapy drugs based on treatment-related changes in the metabolome. <i>PLoS ONE</i> , 2019, 14, e0213942.	1.1	10
52	18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2019, 71, 115-129.	1.8	76
53	Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC). <i>Clinical and Translational Oncology</i> , 2019, 21, 950-953.	1.2	9
54	Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres. <i>World Journal of Gastroenterology</i> , 2019, 25, 5991-6005.	1.4	43

#	ARTICLE	IF	CITATIONS
55	Emerging facets in the treatment of patients with hepatopancreaticobiliary malignancies. <i>Current Problems in Cancer</i> , 2018, 42, 8-11.	1.0	0
56	The importance of quality-of-life management in patients with advanced pancreatic ductal adenocarcinoma. <i>Current Problems in Cancer</i> , 2018, 42, 26-39.	1.0	20
57	Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets. <i>Oncology Research and Treatment</i> , 2018, 41, 298-304.	0.8	8
58	Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma—a meta-analysis. <i>European Journal of Cancer</i> , 2018, 105, 1-9.	1.3	69
59	The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers. <i>PLoS ONE</i> , 2018, 13, e0206007.	1.1	14
60	Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair. <i>Cancer Treatment Reviews</i> , 2018, 70, 168-177.	3.4	55
61	Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. <i>Cancers</i> , 2018, 10, 17.	1.7	21
62	Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment?. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1486-1493.	0.5	11
63	Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 723-731.	1.4	37
64	Selumetinib (Sel) and cisplatin/gemcitabine (CisGem) for advanced biliary tract cancer (BTC): A randomized trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4084-4084.	0.8	4
65	PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. <i>Oncotarget</i> , 2018, 9, 14922-14938.	0.8	29
66	Health-related quality of life, anxiety, depression and impulsivity in patients with advanced gastroenteropancreatic neuroendocrine tumours. <i>World Journal of Gastroenterology</i> , 2018, 24, 671-679.	1.4	17
67	Elderly patients diagnosed with hepatopancreatobiliary malignancies: A challenge beyond resection. <i>Cancer</i> , 2017, 123, 888-890.	2.0	2
68	Treatment Outcomes in 1p19q Co-deleted/Partially Deleted Gliomas. <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 288-294.	0.3	12
69	The dark side of T1 non-appendiceal small bowel neuroendocrine tumors. <i>Human Pathology</i> , 2017, 66, 239-240.	1.1	0
70	Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival. <i>Journal of Neuro-Oncology</i> , 2017, 132, 463-471.	1.4	78
71	HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 141-157.	2.7	119
72	Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw277.	3.0	28

#	ARTICLE	IF	CITATIONS
73	Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. <i>BMC Cancer</i> , 2017, 17, 262.	1.1	16
74	Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma. <i>Current Oncology Reports</i> , 2017, 19, 50.	1.8	17
75	Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib. <i>Clinical and Translational Oncology</i> , 2017, 19, 364-372.	1.2	11
76	Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 909.	1.8	21
77	Long term responders to palliative chemotherapy for advanced biliary tract cancer. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 352-360.	0.6	12
78	Germline mutations in pancreatic cancer and potential new therapeutic options. <i>Oncotarget</i> , 2017, 8, 73240-73257.	0.8	40
79	Pancreatic cancer: Are "liquid biopsies" ready for prime-time?. <i>World Journal of Gastroenterology</i> , 2016, 22, 7175.	1.4	25
80	Detection of Early Tumor Response to Axitinib in Advanced Hepatocellular Carcinoma by Dynamic Contrast Enhanced Ultrasound. <i>Ultrasound in Medicine and Biology</i> , 2016, 42, 1303-1311.	0.7	17
81	Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery. <i>Surgical Oncology</i> , 2016, 25, 223-228.	0.8	13
82	Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems. <i>Future Oncology</i> , 2016, 12, 2561-2578.	1.1	3
83	Telotristat ethyl: a new option for the management of carcinoid syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2487-2498.	0.9	27
84	Predictive and prognostic values of ERCC1 and XRCC1 in biliary tract cancers. <i>Journal of Clinical Pathology</i> , 2016, 69, 695-701.	1.0	10
85	â€œIf You Prick Us, Do We Not Bleed?â€•Whom Should We Choose?. <i>Journal of Clinical Oncology</i> , 2016, 34, 513-514.	0.8	3
86	Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?. <i>Cancer Treatment Reviews</i> , 2016, 44, 26-41.	3.4	45
87	<sup>18</sup> F-FLT PET imaging of cellular proliferation in pancreatic cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 158-169.	2.0	10
88	Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. <i>Annals of Oncology</i> , 2016, 27, 134-140.	0.6	88
89	Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy. <i>World Journal of Gastroenterology</i> , 2016, 22, 6065.	1.4	23
90	Outcome of Adjuvant Therapy in Biliary Tract Cancers. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 382-387.	0.6	36

#	ARTICLE	IF	CITATIONS
91	A phase II trial of secondâ€line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. <i>Cancer</i> , 2015, 121, 1620-1627.	2.0	47
92	Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer. <i>European Journal of Cancer</i> , 2015, 51, 1381-1388.	1.3	19
93	Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. <i>Journal of Neuro-Oncology</i> , 2015, 124, 119-126.	1.4	67
94	To BRCA or Not to PALB. <i>Journal of Clinical Oncology</i> , 2015, 33, 2581-2582.	0.8	1
95	Do recurrent and de novo metastatic biliary tract cancer patients have the same outcome on treatment?. <i>Journal of Clinical Oncology</i> , 2015, 33, 351-351.	0.8	1
96	Patterns of care and treatment outcomes in older patients with biliary tract cancer. <i>Oncotarget</i> , 2015, 6, 44995-45004.	0.8	27
97	Effect of body mass index on outcomes in biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 399-399.	0.8	0
98	Prognostic score in high-grade gastrointestinal neuroendocrine tumours (GI-NETs).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4089-4089.	0.8	0
99	Temozolomide for 1P19Q Co-Deleted and Partially Deleted Gliomas. <i>Annals of Oncology</i> , 2014, 25, iv138.	0.6	0
100	Simple prognostic score for metastatic castrationâ€resistant prostate cancer with incorporation of neutrophilâ€toâ€lymphocyte ratio. <i>Cancer</i> , 2014, 120, 3346-3352.	2.0	128
101	Use and Misuse of Waterfall Plots. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	19
102	Systemic therapy for hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2014, 1, 23-38.	4.2	0
103	RT-19 * PROGNOSTIC VALUE OF EARLY CHANGES IN NEUTROPHIL AND LYMPHOCYTE MEASURES DURING CHEMORADIOTHERAPY FOR GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2014, 16, v191-v191.	0.6	0
104	Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era. <i>Journal of Neuro-Oncology</i> , 2014, 117, 153-160.	1.4	26
105	Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression. <i>Journal of Neuro-Oncology</i> , 2014, 117, 147-152.	1.4	83
106	Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1204-1212.	1.1	519
107	Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. <i>European Journal of Cancer</i> , 2014, 50, 1581-1589.	1.3	119
108	Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju124.	3.0	2,202



#	ARTICLE	IF	CITATIONS
109	RT-20 * DELAYING RADIOTHERAPY IN 1p19q CO-DELETED AND PARTIALLY DELETED GLIOMAS. <i>Neuro-Oncology</i> , 2014, 16, v191-v191.	0.6	0
110	Glioblastoma Treatment in the Elderly in the Temozolomide Therapy Era. <i>Canadian Journal of Neurological Sciences</i> , 2014, 41, 357-362.	0.3	5
111	Effects of statin, aspirin, or metformin use on recurrence free and overall survival in patients with biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 303-303.	0.8	3
112	Patterns of care and treatment outcomes in older patients with biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 315-315.	0.8	1
113	Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective study. <i>European Journal of Cancer</i> , 2013, 49, 329-335.	1.3	104
114	Response to letter â€œOutcome of second-line chemotherapy for biliary tract cancerâ€™. <i>European Journal of Cancer</i> , 2013, 49, 1512-1513.	1.3	1
115	Anaplastic Oligodendroglioma: Advances and Treatment Options. <i>Current Treatment Options in Neurology</i> , 2013, 15, 289-301.	0.7	10
116	State-of-the-art in the management of locally advanced and metastatic gallbladder cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 425-431.	1.1	24
117	Sequence Dependence of MEK Inhibitor AZD6244 Combined with Gemcitabine for the Treatment of Biliary Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 118-127.	3.2	24
118	Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient management. <i>CNS Oncology</i> , 2013, 2, 351-358.	1.2	10
119	Emerging Biomarkers in Glioblastoma. <i>Cancers</i> , 2013, 5, 1103-1119.	1.7	80
120	Neutrophil/lymphocyte ratio (NLR) as a prognostic factor in biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4130-4130.	0.8	1
121	A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 314-314.	0.8	12
122	Antiangiogenic therapies in glioblastoma multiforme. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 643-654.	1.1	29
123	Feasibility and potential benefits of second-line chemotherapy in patients with advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 338-338.	0.8	0
124	Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective study.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14524-e14524.	0.8	0
125	Outcome of adjuvant therapy for biliary tract cancers.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14592-e14592.	0.8	0
126	Management of glioblastoma in the elderly. <i>Clinical Advances in Hematology and Oncology</i> , 2012, 10, 379-86.	0.3	11



#	ARTICLE	IF	CITATIONS
127	Retrospective review of patients with a diagnosis of testicular germ cell tumor seen in Waterford Regional Hospital, Ireland, in a 5.5-year period.. Journal of Clinical Oncology, 2011, 29, e15111-e15111.	0.8	0
128	Population profile for squamous cell carcinoma and adenocarcinoma of cervix in Waterford Regional Hospital, Ireland.. Journal of Clinical Oncology, 2010, 28, e15557-e15557.	0.8	0
129	Emergence of MRSA in positive blood cultures from patients with febrile neutropeniaâ€”a cause for concern. Supportive Care in Cancer, 2008, 16, 1085-1088.	1.0	48
130	Lipids and essential fatty acids in patients presenting with self-harm. British Journal of Psychiatry, 2007, 190, 112-117.	1.7	75
131	Swim Stress Increases the Potency of Glycine at the N-Methyl-d-Aspartate Receptor Complex. Journal of Neurochemistry, 2002, 64, 925-927.	2.1	36
132	3,4-methylenedioxyamphetamine (MDMA; Ecstasy) administration produces dose-dependent neurochemical, endocrine and immune changes in the rat. Human Psychopharmacology, 1999, 14, 95-104.	0.7	16
133	Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. European Journal of Pharmacology, 1999, 364, 123-132.	1.7	85
134	Royal academy of medicine in Ireland section of biomedical sciences. Irish Journal of Medical Science, 1998, 167, 51-63.	0.8	0
135	Acute 3,4-methylenedioxyamphetamine (MDMA) administration produces a rapid and sustained suppression of immune function in the rat. Immunopharmacology, 1998, 38, 253-260.	2.0	57
136	Chronic imipramine treatment upregulates IR2-imidazoline receptive sites in rat brain. Neurochemistry International, 1997, 30, 101-107.	1.9	12
137	BIMT 17: a putative antidepressant with a fast onset of action?. Psychopharmacology, 1997, 134, 378-386.	1.5	34
138	Royal academy of medicine in Ireland section of biomedical sciences. Irish Journal of Medical Science, 1996, 165, 224-238.	0.8	0
139	Some behavioural and neurochemical effects of ipsapirone in two rodent models of depression. Journal of Psychopharmacology, 1996, 10, 126-133.	2.0	5
140	The effect of acute MDMA administration on body temperature, serum corticosterone and neurotransmitter concentrations in male and female rats. Human Psychopharmacology, 1995, 10, 373-383.	0.7	16
141	Some behavioural and neurochemical aspects of subacute ( $\hat{\pm}$ )3,4-methylenedioxyamphetamine administration in rats. Pharmacology Biochemistry and Behavior, 1995, 52, 479-484.	1.3	68
142	Royal academy of medicine in Ireland section of biomedical sciences. Irish Journal of Medical Science, 1995, 164, 311-319.	0.8	0
143	Royal academy of medicine in Ireland section of biomedical sciences. Irish Journal of Medical Science, 1994, 163, 258-268.	0.8	1
144	Carboplatin-etoposide chemotherapy for patients with advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC); outcomes from a European Neuroendocrine Tumour Society Centre of Excellence. Endocrine Abstracts, 0, , .	0.0	1